USPTO serial 78298515
Reviewed by CopyMark Law Group
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
G. Mathew Lombard
G MATHEW LOMBARD TRADEMARK DEPARTMENTBRISTOL-MYERS SQUIBB COMPANY345 PARK AVENEW YORK, NY 10154| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment and prevention of diabetes, cardiovascular diseases, central nervous system diseases and disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases; antibiotics | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 5, 2004 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Jul 19, 2004 | PAPER RECEIVED | — | |
| Jul 7, 2004 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jul 7, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 6, 2004 | PAPER RECEIVED | — | |
| Mar 31, 2004 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 26, 2004 | DOCK | ASSIGNED TO EXAMINER | — |